CHM — Chimeric Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- AU$6.35m
- AU$5.57m
- AU$3.97m
Annual balance sheet for Chimeric Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | R2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 22.4 | 18.4 | 2.36 | 3.05 | 5.76 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.024 | 2.66 | 6.66 | 0.087 | 4.55 |
| Total Other Current Assets | |||||
| Total Current Assets | 22.7 | 21.2 | 9.35 | 3.22 | 10.5 |
| Net Property, Plant And Equipment | 0.014 | 0.016 | 0.006 | 0.001 | 0 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 36.5 | 34.9 | 22.4 | 15.3 | 21.6 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.35 | 9.02 | 14.7 | 10.1 | 14.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.4 | 9.17 | 16.7 | 12.8 | 19.6 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 25.1 | 25.7 | 5.66 | 2.47 | 1.97 |
| Total Liabilities & Shareholders' Equity | 36.5 | 34.9 | 22.4 | 15.3 | 21.6 |
| Total Common Shares Outstanding |